Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Sodium Trifluoromethanesulfinate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN109825849A reveals a metal-free electrochemical route for trifluoromethyl vinylic compounds, offering significant cost reduction and supply chain reliability for fine chemical manufacturing.
Patent CN114773185B reveals a copper-catalyzed deoxyfluorination method. Offers cost-effective, scalable production of high-purity benzoyl fluoride intermediates for pharma.
Patent CN110590774B discloses a green photocatalytic method for C3-trifluoromethylation of imidazo-fused rings, offering mild conditions and high purity for pharmaceutical intermediates.
Patent CN110590774B details a green photocatalytic route for C3-trifluoromethylation, offering mild conditions and high purity for pharmaceutical intermediates.
Patent CN111235594A details a green electrochemical route for aryl trifluoromethylthio compounds, offering cost-effective and scalable solutions for pharmaceutical and agrochemical manufacturing.
Patent CN111205185B details a green Mn-catalyzed synthesis of beta-trifluoromethyl alcohols using visible light, offering cost-effective solutions for pharmaceutical intermediates.
Patent CN114214646A details a green electrochemical route for 2-trifluoromethyl-alpha-carbonyl dithioketene, offering cost-effective pharma intermediate manufacturing without transition metals.
Patent CN113444076A details a green three-component synthesis for fluorinated quinoxalinones, offering recyclable catalysis and reduced metal residues for pharmaceutical manufacturing.
Patent CN113444076A reveals a recyclable chitosan-copper catalyst for synthesizing fluorinated quinoxalinones, offering sustainable cost reduction and high purity for pharma manufacturing.
Solve sulfur-containing isoindolinone synthesis challenges: 77% yield, no CO, simplified process. Reduce supply chain risks for pharma intermediates.